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We performed a phase II study of combination chemotherapy with irinotecan, 5-fluorouracil (5-FU) and leucovorin in metastatic
gastric cancer patients who were previously treated with taxane and cisplatin, to evaluate the antitumour activity and toxicity of the
combination chemotherapy. The metastatic gastric adenocarcinoma patients who were previously treated with taxane and cisplatin
combination as first line, and had at least one measurable lesion, 0–2 ECOG performance status and adequate organ functions, were
considered eligible. They received irinotecan (150mgm
 2, day 1) and leucovorin (100mgm
 2, day 1), followed by continuous
infusion of 5-FU (1000mgm
 2day
 1, days 1 and 2) every 2 weeks. Treatment was continued until progression of disease was
observed. In all, 64 patients were treated with this combination chemotherapy. The median age of the patients was 55 years (range,
33–74 years), and the median ECOG performance status was 1 (0–1, 61 (95%)). Out of 64 patients, 57 were assessable for
response. Among 57 assessable patients, no complete response and 12 partial responses were observed (overall response rate, 21%;
95% confidence interval (CI), 10–32%). Stable disease was observed in 14 patients (25%) and progressive disease in 31 patients
(54%). The median time to progression was 2.5 months (95% CI, 1.6–3.4) and the median overall survival since the start of the
second-line modified FOLFIRI was 7.6 months (95% CI, 6.5–8.7). Grade 3–4 haematologic toxicities included neutropenia in seven
patients (11%) and thrombocytopenia in five patients (8%). Grade 3–4 nonhaematologic toxicities included diarrhoea in two patients
(3%) and vomiting in two patients (3%). There were no treatment-related deaths. The combination of irinotecan, 5-FU and
leucovorin showed moderate activity and favourable toxicity profile as a second-line treatment in metastatic gastric cancer patients,
who were previously treated with taxane and cisplatin.
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Gastric adenocarcinoma is the most common malignancy and one
of the major causes of cancer death in Korea (Bae et al, 2002). The
prognosis of unresectable gastric cancer has been improved by
palliative chemotherapy (Murad et al, 1993; Pyrhonen et al, 1995;
Glimelius et al, 1997), but median overall survival (OS) rarely
exceeds 1 year (Wils, 1998). Studies showed the benefit of
combination regimens, such as fluorouracil (FU), doxorubicin
and methotrexate (FAMTX) (Wils, 1998) or etoposide, leucovorin
(LV) and FU (ELF), over best supportive care (Murad et al, 1993;
Pyrhonen et al, 1995; Glimelius et al, 1997). Other combination
regimens investigated include epirubicin, cisplatin and infusional
FU (ECF) and 5-day infusional FU plus cisplatin (FUP). However, a
randomised phase b trial showed that there were no significant
differences in response rates (RRs) or survival durations among
the combination regimens. Although there are no standard first-
line chemotherapeutic drugs in unresectable gastric cancer, ECF is
generally considered as a standard therapy in Europe after the
results from phase III trial have been published (Webb et al, 1997).
Taxane and cisplatin has been used as a first-line chemotherapy
with various schedules and doses since the late 1990s (Roth et al,
2000; Ridwelski et al, 2001; Kornek et al, 2002; Lee et al, 2004).
Taxane and cisplatin chemotherapy has produced 30–50% of RRs
as a first-line treatment, but the diseases of responding and
nonresponding patients eventually progress (Roth et al, 2000;
Ridwelski et al, 2001; Kornek et al, 2002; Lee et al, 2004). A
randomised phase III trial showed a higher RR (39 vs 23%) and
longer time to progression (TTP; 5.2 vs 3.7 months) in DCF
(docetaxel, cisplatin, 5-fluorouracil) arm when compared to CF
(cisplatin, 5-fluorouracil) arm (Ajani et al, 2003).
In addition to novel combinations of established agents, the use
of newer agents, such as irinotecan, is under investigation.
Irinotecan, a topoisomerase I inhibitor, proved to have a clinical
activity against unresectable gastric cancer. The RR of irinotecan
alone has been reported to be 20–25% in phase II studies
(Futatsuki et al, 1994; Kohne et al, 2003), regardless of prior
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schemotherapy. Combination of irinotecan with cisplatin showed
the RR of 48% in metastatic gastric cancer patients who had
received no or one chemotherapy regimen (Boku et al, 1999), and
combination with 5-fluorouracil (5-FU) produced the RRs of 22–
42.4% in previously untreated gastric adenocarcinoma patients
(Blanke et al, 2001; Assersohn et al, 2004; Bouche et al, 2004).
We performed a phase II study of a combination chemotherapy
with irinotecan, leucovorin and 5-FU in metastatic gastric cancer
patients, who were previously treated with taxane and cisplatin
combination, to evaluate the antitumour activity and toxicity of
the combination chemotherapy.
MATERIALS AND METHODS
Eligibility
Patients were eligible with histologically confirmed, unresectable
adenocarcinoma of the stomach. They were required to be between
18 and 75 years, have at least one measurable lesion, Eastern
Cooperative Oncology Group (ECOG) performance status p2, and
have a life expectancy at least 3 months. Eligible patients must
have received one prior palliative chemotherapy with taxane and
cisplatin. Adequate haematologic function (absolute neutrophil
count (ANC) X1500mm
 3, platelet count X100000mm
 3),
hepatic function (aspartate aminotransferase/alanine aminotrans-
ferase (AST/ALT) p3.0 times the upper normal limit (UNL),
bilirubin p1.25 times the UNL), and renal function (serum
creatinine p1.5 times the UNL) were required. Prior history of
another malignancy within 5 years of study entry, apart from basal
cell carcinoma of the skin or carcinoma in situ of the uterine
cervix, precluded participation in the current trial. Patients with
concurrent uncontrolled medical illness were also excluded. All
patients provided a written informed consent according to the
guideline provided by the institutional review board.
Chemotherapy
Chemotherapy was administered through a central venous catheter
(Hickman catheter or chemoport) placed in the subclavian vein,
and ambulatory pumps were used for continuous infusion of 5-FU.
Irinotecan (150mgm
 2, over 90min, day 1), followed by
leucovorin (100mgm
 2, over 2h, day 1), and then followed by
5-FU (1000mgm
 2, over 24h, day 1 and 2) were given as an
intravenous infusion. Cycles were repeated every 2 weeks. Before
irinotecan infusion, 0.3mg atropine was subcutaneously adminis-
tered to prevent cholinergic syndrome. A 5-hydroxytryptamine
type 3 receptor antagonist was given as antiemetic prophylaxis
immediately before chemotherapy and loperamide was provided
for diarrhoea. Treatment was continued until documented disease
progression, unacceptable toxicity, patients’ refusal, or physicians’
decision.
Dose modification
Chemotherapy was withheld if the ANC was o1500mm
 3 or the
platelet count was o100000mm
 3 on day 1. In this case, the
complete blood cell count (CBC) was repeated at least weekly
and chemotherapy was restarted as soon as the ANC reached
X1500mm
 3 and platelet count X100000mm
 3. If nadir ANC
was less than 500mm
 3, or the nadir platelet count was less than
50000mm
 3, the doses of irinotecan and 5-FU were reduced to 120
and 800mgm
 2, respectively. If grade 3–4 nonhaematologic
toxicity other than alopecia, the treatment was withheld until
recovery to grade 0 or 1 and the doses of irinotecan and 5-FU were
reduced to 120 and 800mgm
 2, respectively. If patients required a
delay of longer than 2 weeks, they were treated off the protocol.
Assessment of efficacy and toxicity
At study entry, the following investigations were performed: full
history taking and physical examination, CBC, chemistry, chest X-
ray and computed tomography scan. History taking, physical
examination, CBC and chemistry were repeated before each cycle.
Computed tomography scans were performed to document the
disease extent and to evaluate response to treatment, every three
cycles and when needed for the confirmation of response and
suspected disease progression. Responses were classified according
to World Health Organization (WHO) criteria. Patients were
considered assessable for response if they had early disease
progression or had received at least three cycles of treatment with
at least one tumour assessment. Response rate was calculated as
the ratio of number of patients who achieved complete responses
or partial responses to the number of assessable patients. Duration
of response was calculated from the first day of treatment to the
date on which progressive disease was first observed or of the last
follow-up, for the group of responding patients. Time to
progression was calculated from the first day of treatment to the
date on which progressive disease was first observed or of the last
follow-up. Overall survival was calculated from the first day of
treatment to the date of death or last follow-up.
Toxicity was graded according to National Cancer Institute
common toxicity criteria (NCI-CTC) version 2.0. (NCI-CTC Web
site). The severity of any toxicities not defined in the NCI-CTC
were graded as 1¼mild, 2¼moderate, 3¼severe or 4¼very
severe.
Statistical analysis
Descriptive statistics were reported as proportions and medians.
Kaplan–Meier estimates were used in the analysis of all time-to-
event variables, and the 95% confidence interval (CI) for the
median time to event was computed. The dose intensity (DI)
was calculated as the ratio of the total dose (expressed in
milligrams) per square meter of the patient, divided by the total
treatment duration expressed in days. In this calculation, the
end of treatment was considered to be 14 days after day 1 of
the last cycle of chemotherapy. The relative DI was calculated as
the ratio of the DI actually delivered to the DI planned by the
protocol.
According to Simon’s two-stage optimal design, a sample size of
55 was required to accept the hypothesis that the true RR is greater
than 25% with 90% power, and to reject the hypothesis that the RR
is less than 10% with 5% significance. At the first stage, if there
were fewer than four responses out of the initial 31 patients, the
study would terminate. Although the target number of patients was
55, we planned to recruit 20% more than the target number of
patients considering dropout.
SPSS for Windows (SPSS Inc., Chicago, IL, USA) was used for
statistical analysis.
RESULTS
Patient characteristics
From November 2001 to July 2003, 64 patients were enrolled. The
clinical characteristics of enrolled patients are shown in Table 1.
The median age of the patients was 55 years (range, 33–74 years)
and the majority (73%) of patients was male. The median ECOG
performance status was one (0–1, 61 (95%)), and all patients had
metastatic disease at study entry. Major involved organs were liver
and intra-abdominal lymph nodes. Regimens of the prior
chemotherapy are listed in Table 1, and all of theses patients
showed progressive disease after taxane and cisplatin before entry
into this study.
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The patients received a median of six (range, 1–9) cycles. The
average relative dose-intensities were 0.87 for irinotecan, 0.87 for
5-FU and 0.89 for leucovorin. Dose reduction was required in 11
patients (37 cycles) and treatment was delayed in 23 patients (59
cycles). The most common causes of dose reduction were
neutropenia (64%), thrombocytopenia (45%), diarrhoea (18%)
and vomiting (18%).
Response rate
In all, 57 patients were assessable for treatment response. Seven
patients were excluded from the response analysis; four
patients received one cycle and three patients two cycles
of chemotherapy. Five of seven patients excluded from the
analysis were lost to follow-up and the remaining two patients
refused further treatment due to asthenia. Among 57 assessable
patients, no complete response and 12 partial responses were
observed (overall RR, 21%; 95% CI, 10–32%). Stable disease was
observed in 14 patients (25%) and progressive disease in 31
patients (54%) (Table 2). The median duration of response was 5.8
months (95% CI, 4.0–7.6). The differences in RRs were not
observed according to baseline patients’ characteristics (age, sex,
performance status, involved organs and previous chemotherapy
regimen).
Survival
All 64 patients were in included in the survival analysis on an
intent-to-treat basis. The median follow-up time was 22 months
(95% CI, 20–25). The median TTP was 2.5 months (95% CI, 1.6–
3.4) and the median OS was 7.6 months (95% CI, 6.5–8.7). The
differences in TTP and OS were not observed according to age, sex,
performance status, involved organs and previous chemotherapy
regimen. The TTP and OS curves are shown in Figure 1.
Toxicity
Toxicities observed during the treatment are listed in Table 3. NCI-
CTC grade 3 or 4 haematologic toxicities included neutropenia in
Table 1 Patient characteristics
Patient characteristics No. of patients (N¼64) %
Age, years —
Median (range) 55 (33–74)
Sex
Female 17 27
Male 47 73
ECOG status
03 5
15 8 9 0
23 5
First-line regimen
Paclitaxel/CDDP 8 14
Docetaxel/CDDP 33 50
EDP 23 36
Organ involved
Lymph nodes 34 41
Liver 29 35
Peritoneum 6 7
Ovary 5 6
Others 4 5
Others: pancreas (two), bone (two), lung (one), adrenal (one), uterus (one), ureter
(one). CDDP, cisplatin; EDP, epirubicin/docetaxel/cisplatin.
Table 2 Response rate
Response Number of patients (%)
Complete response 0
Partial response 12 (21%)
Stable disease 14 (25%)
Progressive disease 31 (54%)
Total assessable patients 57
Table 3 Grade 3/4 adverse events (N¼64)
Toxicity Number of patients (%)
Neutropenia 7 (11%)
Thrombocytopenia 5 (8%)
Diarrhoea 2 (3%)
Vomiting 2 (3%)
Total enrolled patients 64
14 12 10 8 6 4 2 0
OS months
OS months
30 20 10 0
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Median TTP: 2.5 months 
Median OS: 7.6 months
Figure 1 Time to progression and OS.
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Two patients (3%) with neutropenic fever and four patients (6%)
with grade 3 or 4 diarrhoea/vomiting required hospital admissions.
There were no treatment-related deaths.
DISCUSSION
The prognosis of unresectable gastric cancer has remained poor
despite new palliative treatment modalities. Response rates as a
frontline of various combination chemotherapy regimens ranged
between 30 and 70%, but median OS rarely exceeded 10 months
(Murad et al, 1993; Pyrhonen et al, 1995; Glimelius et al, 1997;
Wils, 1998). Taxane and cisplatin combination chemotherapy
regimen has been increasingly used as a first-line treatment in
unresectable gastric cancer. Phase a studies with paclitaxel or
docetaxel in combination with cisplatin with or without 5-FU have
demonstrated RRs of 37–51% and OSs of 9–14 months in
chemotherapy-naı ¨ve patients (Kollmannsberger et al, 2000;
Ridwelski et al, 2001; Polee et al, 2002). Other phase II studies
have employed the combination of irinotecan and cisplatin; RRs
have ranged from 28 to 59% in chemotherapy-naı ¨ve patients, with
corresponding OSs of 9–11 months (Shirao et al, 1997; Boku et al,
1999; Pozzo et al, 2001; Ajani et al, 2002). As most of the patients
with unresectable gastric cancer eventually progress after the first-
line chemotherapy, the second-line chemotherapy should be
developed without cross-resistance to first-line chemotherapy.
We studied a new second-line combination regimen, the modified
FOLFIRI (irinotecan, leucovorin and 5-FU), in patients who had
failed to taxane and cisplatin combination. We had used the
reduced dose of irinotecan and 5FU as would be routinely used in
similar regimens as in advanced colorectal cancer (i.e. the FOLFIRI
regimen). The low dose of irinotecan (150mgm
 2, every 2 weeks)
used in our study was based on the previous phase a studies
conducted in Japan (Futatsuki et al, 1994; Bleiberg, 1999), which
demonstrated modest antitumour activities in unresectable gastric
cancer patients with irinotecan 150mgm
 2 every 2-week schedule.
This regimen showed a RR of 21% in assessable patients and of
19% in all patients as a second-line treatment. In this phase II
study, the median TTP was 2.5 months (95% CI, 1.6–3.4 months)
and the median OS was 7.6 months (95% CI, 6.5–8.7 months). A
previous study of irinotecan, 5-FU and leucovorin against gastric
cancer yielded a RR of 22–40% and OS of 7.6–11.3 months as a
first-line treatment (Blanke et al, 2001; Bouche et al, 2004). This
three-drug combination regimens with different treatment scheme
showed a RR of 29% and an OS of 6.4 months as a second-line
treatment against oesophageal and gastric cancer (Assersohn et al,
2004).
The regimen showed a favourable toxicity profile. There were no
treatment-related deaths. Although haematologic toxicity was
reported, the incidence of grade 3–4 haematologic toxicity was
approximately 10% (neutropenia in 11% and thrombocytopenia in
8%). NCI-CTC grades 3 or 4 nonhaematologic toxicities were
minimal in incidence and all manageable (diarrhoea in 3% and
vomiting in 3%). Two previous studies using a similar regimen in
gastric cancer showed 36% (Blanke et al, 2001) and 26%
(Assersohn et al, 2004) of grade 3–4 neutropenia, and 28%
(Blanke et al, 2001) and 8% (Assersohn et al, 2004) of grade 3–4
diarrhoea. The significantly low rate of grade 3–4 toxicities in this
study when compared to other irinotecan-based trials may be
explained by the ethnic difference or the continuous infusion of
5-FU or the dose intensity of irinotecan. The ethnic difference in
tolerability may be explained by the UDP-glucuronosyltranferase
1A1 genotype, predictive factor of severe neutropenia (Innocenti
et al, 2004). In addition, Blanke et al used 5-FU bolus, whereas we
used continuous infusion of 5-FU. The dose intensities of
irinotecan in the previous studies were 83mgm
 2 per week
(125mgm
 2 per week in the first 4 weeks) (Blanke et al, 2001) and
90mgm
 2 per week (Assersohn et al, 2004), but the dose intensity
in this study was 75mgm
 2 per week.
Based on a comparable activity and a favourable safety profile to
other second-line regimens, the combination chemotherapy with
irinotecan, 5-FU and leucovorin should be considered as a second-
line treatment in taxane- and platinum-treated, unresectable
gastric cancer.
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